Last reviewed · How we verify
Pf-07220060 (pf-07220060)
PF-07220060 is an investigational drug developed by Pfizer Inc. It is currently in clinical trials and has not yet received FDA approval. The drug is being evaluated for its potential in treating various conditions, but specific details about its mechanism of action, safety profile, and commercial prospects are limited due to its developmental stage. Early clinical data suggest that it may have a unique mechanism of action, but more research is needed to fully understand its therapeutic potential and safety. The drug's development timeline and regulatory milestones are ongoing, and Pfizer is actively working to advance it through the clinical trial process.
At a glance
| Generic name | pf-07220060 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Small molecule inhibitor |
| Target | Specific protein involved in disease pathways |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | Not available |
Approved indications
- Multiple Myeloma
Pipeline indications
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C9 inhibitors
- CYP2C9 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP1A2 inhibitors
Key clinical trials
- A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults (PHASE1)
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease (PHASE3)
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (PHASE2)
- Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants (PHASE1)
- A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants (PHASE1)
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 (PHASE1)
- A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pf-07220060 CI brief — competitive landscape report
- Pf-07220060 updates RSS · CI watch RSS
- Pfizer portfolio CI